Novacyt (ALNOV) Status update summary

Strategic rationale and acquisition benefits

• Acquisition of Southern Cross Diagnostics aligns with objectives of growth, profitability, and portfolio expansion.

• Deal is immediately accretive, expands product range, and provides direct access to key customers in Australia and New Zealand.

• Direct customer relationships will enhance product innovation and implementation through better feedback.

• Opportunity to leverage Southern Cross’s products for broader global distribution.

• Integration includes full staff retention and leadership commitment from the former owner, supporting regional expertise.

Financial terms and capital raise

• Initial cash consideration of AUD 8.5 million, representing a 4x EBITDA multiple.

• Contingent consideration up to AUD 16.5 million, tied to EBITDA targets over four years; full payout requires over AUD 30 million EBITDA.

• Preferential subscription rights process enabled a capital raise of around EUR 785 thousand, oversubscribed by 25%.

• Over 50% of new shares issued to the former owner, who invested about EUR 415 thousand.

• Net proceeds of EUR 580 thousand will strengthen the balance sheet.

Operational focus and future outlook

• Emphasis on increased communication, regular updates, and more investor engagement.

• Plans for new product launches in 2026 and strengthening commercial partnerships.

• Continued focus on cost control, cash preservation, and business simplification amid uncertain markets.

• Synergy opportunities expected from the integration of Southern Cross.

• Upcoming results announcement scheduled for end of April.